Efficacy and safety of gene therapy approaches for malignant gliomas: A systematic review and meta-analysis

IF 2.3 4区医学 Q3 ONCOLOGY

Current Problems in Cancer Pub Date : 2025-01-23 DOI:10.1016/j.currproblcancer.2025.101183

Elnaz Amanzadeh Jajin, Saeed Oraee-Yazdani, Alireza Zali, Roozbeh Tavanaei

{"title":"Efficacy and safety of gene therapy approaches for malignant gliomas: A systematic review and meta-analysis","authors":"Elnaz Amanzadeh Jajin, Saeed Oraee-Yazdani, Alireza Zali, Roozbeh Tavanaei","doi":"10.1016/j.currproblcancer.2025.101183","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Malignant gliomas are the most aggressive brain tumors with no certain therapeutic methods. Nowadays, novel treatment methods are introduced for gliomas among which gene therapy is known as a promising and robust method. In this method, genes with key roles in the prevention of cell cycle or induction of cell suicide are transferred to the tumor site using vectors. Viral vectors are the most popular transfer methods, while the liposomes are also used for gene therapy.</div></div><div><h3>Methods</h3><div>This meta-analysis and systematic review was performed based on PRISMA guidelines. We performed a comprehensive search in databases including PubMed, Embase, and clinicaltrial.gov. After processing and filtering the articles, phase 1 clinical trials were chosen for the evaluation of the efficacy and safety of gene therapy for malignant gliomas.</div></div><div><h3>Results</h3><div>The obtained results showed that gene therapy increases overall survival (OS) and progression-free survival (PFS) in two years of follow-up. Subgroup analysis also showed that cytokines exhibit the highest effectiveness compared to suicide genes and oncolytic genes. It was found that gene therapy is more efficient for recurrent gliomas than primary gliomas. The subgroup analysis for vectors revealed that Adenovirus is the most effective for increasing the OS in malignant glioma patients.</div></div><div><h3>Conclusion</h3><div>Gene therapy is an immunotherapy method for malignant gliomas following the standard treatment approach. Considering the effectiveness of gene therapy on the survival of patients, it is hoped that solving related issues with gene therapy will help to increase the OS rate in this malignant disease.</div></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"55 ","pages":"Article 101183"},"PeriodicalIF":2.3000,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Problems in Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0147027225000108","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Malignant gliomas are the most aggressive brain tumors with no certain therapeutic methods. Nowadays, novel treatment methods are introduced for gliomas among which gene therapy is known as a promising and robust method. In this method, genes with key roles in the prevention of cell cycle or induction of cell suicide are transferred to the tumor site using vectors. Viral vectors are the most popular transfer methods, while the liposomes are also used for gene therapy.

Methods

This meta-analysis and systematic review was performed based on PRISMA guidelines. We performed a comprehensive search in databases including PubMed, Embase, and clinicaltrial.gov. After processing and filtering the articles, phase 1 clinical trials were chosen for the evaluation of the efficacy and safety of gene therapy for malignant gliomas.

Results

The obtained results showed that gene therapy increases overall survival (OS) and progression-free survival (PFS) in two years of follow-up. Subgroup analysis also showed that cytokines exhibit the highest effectiveness compared to suicide genes and oncolytic genes. It was found that gene therapy is more efficient for recurrent gliomas than primary gliomas. The subgroup analysis for vectors revealed that Adenovirus is the most effective for increasing the OS in malignant glioma patients.

Conclusion

Gene therapy is an immunotherapy method for malignant gliomas following the standard treatment approach. Considering the effectiveness of gene therapy on the survival of patients, it is hoped that solving related issues with gene therapy will help to increase the OS rate in this malignant disease.

查看原文本刊更多论文

恶性胶质瘤基因治疗方法的疗效和安全性：一项系统回顾和荟萃分析：nrnr22.5 nrnr1011.413.511.9 nrnrnr。

背景：恶性胶质瘤是最具侵袭性的脑肿瘤，目前尚无特定的治疗方法。近年来，神经胶质瘤的治疗方法越来越多，其中基因治疗被认为是一种很有前途的治疗方法。在这种方法中，利用载体将在预防细胞周期或诱导细胞自杀中起关键作用的基因转移到肿瘤部位。病毒载体是最流行的转移方法，而脂质体也用于基因治疗。方法：根据PRISMA指南进行meta分析和系统评价。我们在PubMed、Embase和clinicaltrial.gov等数据库中进行了全面的搜索。对文章进行处理和筛选后，选择1期临床试验，评价基因治疗恶性胶质瘤的疗效和安全性。结果：获得的结果显示，基因治疗在两年的随访中提高了总生存期（OS）和无进展生存期（PFS）。亚组分析还显示，细胞因子比自杀基因和溶瘤基因表现出最高的有效性。研究发现基因治疗复发性胶质瘤比原发性胶质瘤更有效。载体亚群分析显示，腺病毒对提高恶性胶质瘤患者OS最有效。结论：基因治疗是恶性胶质瘤继标准治疗方法后的一种免疫治疗方法。考虑到基因治疗对患者生存的影响，希望通过基因治疗解决相关问题，有助于提高这种恶性疾病的OS率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Problems in Cancer 医学-肿瘤学

CiteScore

5.10

自引率

0.00%

发文量

审稿时长

15 days

期刊介绍： Current Problems in Cancer seeks to promote and disseminate innovative, transformative, and impactful data on patient-oriented cancer research and clinical care. Specifically, the journal''s scope is focused on reporting the results of well-designed cancer studies that influence/alter practice or identify new directions in clinical cancer research. These studies can include novel therapeutic approaches, new strategies for early diagnosis, cancer clinical trials, and supportive care, among others. Papers that focus solely on laboratory-based or basic science research are discouraged. The journal''s format also allows, on occasion, for a multi-faceted overview of a single topic via a curated selection of review articles, while also offering articles that present dynamic material that influences the oncology field.